Antibiotic sensitivity of bacteria on the oral mucosa after hematopoietic cell transplantation by Soga, Yoshihiko et al.
1 
 
 
Antibiotic sensitivity of bacteria on the oral mucosa 
after hematopoietic cell transplantation 
 
Yoshihiko Soga1, Yoshinobu Maeda2, Mitsune Tanimoto2, 
 Takayuki Ebinuma3, Hiroshi Maeda3, Shogo Takashiba3 
 
1) Division of Hospital Dentistry, Central Clinical Department, Okayama University 
Hospital, Japan 
2) Department of Hematology, Oncology and Respiratory Medicine, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama, Japan 
3) Department of Pathophysiology - Periodontal Science, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 
 
*Corresponding author: 
Yoshihiko Soga, D.D.S., Ph.D. 
Vice Director 
Division of Hospital Dentistry, Central Clinical Department 
Okayama University Hospital 
2-5-1 Shikata-cho, Okayama 700-8525, Japan 
Tel: +81-86-235-6588 Fax: +81-86-235-6588 
e-mail: y_soga@md.okayama-u.ac.jp 
2 
 
Keywords: 
antibiotic sensitivity, bacteria, oral mucosa, mucositis, hematopoietic cell 
transplantation 
 
3 
 
We reported recently that bacterial substitution of mainly coagulase-negative 
staphylococci (CoNS) for streptococci occurred frequently on the oral buccal mucosa 
after hematopoietic cell transplantation (HCT), and other bacterial species not usually 
found in the normal flora were also identified [1]. We also reported that 
multidrug-resistant opportunistic bacteria appearing in the gingiva may be involved in 
fatal sepsis [2]. These observations prompted an interest in the antibiotic sensitivity of 
bacteria after HCT, which may explain the bacterial substitution on oral mucosa after 
HCT. Therefore, we performed a pilot study to determine the antibiotic sensitivity of 
bacteria on the oral mucosa after HCT. 
We examined the antibiotic sensitivity of bacteria detected after HCT, focusing 
on the period from day 0 to 13, when the severity of clinically evident mucosal damage 
generally peaks and can cause bacteremia via the oral mucosa [3 – 5]. A total of 9 
consecutive patients (M: 4, F: 5, 47.3 ± 11.0 y) receiving HCT at Okayama University 
Hospital were enrolled in this study. The diseases in these 9 patients were as follows: 
acute myelogenous leukemia (n = 3), myelodysplastic syndrome (n = 1), and malignant 
lymphoma (n = 5). Autologous HCT, conventional allogeneic HCT, and 
reduced-intensity HCT were administered to 2 (M: 2, F: 0, av.: 61.0 y), 5 (M: 0, F: 5, 
39.4 ± 7.7 y), and 2 (M: 2, F: 0, av.: 53.5 y) patients, respectively. Informed consent for 
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examination of oral bacteria was obtained from each subject, and the Ethical Committee 
of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical 
Sciences approved this study (No. 263). General infection control and oral management 
were performed as described in our previous report [1]. Briefly, fluoroquinolone for 
prophylaxis against bacterial infection was administered orally. Neutropenic fever was 
managed according to the guidelines of Hughes et al. [6]. A fourth-generation 
cephalosporin (e.g., cefepime) or carbapenem (e.g., meropenem) was administered 
intravenously as empirical antibiotic therapy.  
Buccal mucosal swab samples were obtained from each patient twice with a 
one-week interval from day 0 to +13. Samples were obtained about 2 h after breakfast 
by swabbing from the whole surface of the buccal mucosa. All samples were plated onto 
agar plates under aerobic conditions, and 2 – 5 major colonies that were visibly different 
from each other were collected. A total of 67 colonies were collected from 9 HCT 
patients. Collected colonies were subjected to microbial identification and antibiotic 
sensitivity test. Identification of colonies thus obtained was performed using rapid ID 32 
STREP API®, rapid ID 32 E API®, or ID 32 GN API® identification kits (Japan 
bioMérieux, Tokyo, Japan) according to the manufacturer’s instructions. Due to the 
laboratory’s capacity, almost all bacterial identification was limited to the genus level. 
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Antibiotic sensitivity test was performed by the broth microdilution method, and the 
minimum inhibitory concentration (MIC) was determined. Definitions of susceptibility, 
intermediate resistance, and resistance were made according to the National Committee 
for Clinical Laboratory Standards (NCCLS) susceptibility testing guidelines for 
bacterial species. Abbreviations for antibiotics are as follows: PCG, benzylpenicillin; 
ABPC, amoxicillin; MPIPC, mecillinam; CVA/AMPC, clavulanate/amoxicillin; CCL, 
cefaclor; CDTR, cefditoren; CFPM, cefepime; CEZ, Cefazolin; CTM, cefotiam; CTX, 
cefotaxime; CZOP, ceftizoxime; CPR, cefpirome; FMOX, flomoxef; IPM/CS, 
imipenem/cilastatin; MEPM, meropenem; GM, gentamicin; CAM, clarithromycin; 
CLDM, clindamycin; MINO, minocycline; CP, chloramphenicol; LVFX, levofloxacin. 
A total of 38 Streptococcus spp. colonies were identified and subjected to 
sensitivity test for the following antibiotics: PCG, ABPC, CCL, CDTR, CFPM, CTM, 
CTX, CZOP, CPR, IPM/CS, MEPM, CAM, CLDM, MINO, CP, and LVFX. 7.9% – 
42.1% of detected streptococcal colonies were resistant or showed intermediate 
resistance to penicillins (PCG, ABPC) and cephems (CCL, CDTR, CFPM, CTM, CTX, 
CZOP, CPR). Furthermore, 28.9% – 55.2% of these colonies were also resistant or 
showed intermediate resistance to macrolides (CAM, CLDM). A total of 9 CoNS spp. 
colonies were identified and subjected to sensitivity test for the following antibiotics: 
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PCG, MPIPC, ABPC, CCL, CFPM, CEZ, CTM, CZOP, FMOX, IPM/CS, CVA/AMPC, 
and FOM. All of the CoNS detected after HCT showed resistance or intermediate 
resistance to CFPM (100%), which was our first-choice antibiotic in empirical antibiotic 
therapy. CoNS also showed high degrees of resistance to penicillins (55.6% – 100%), 
e.g., PCG, MPIPC, and ABPC. A total of 2 colonies of Staphylococcus aureus were 
identified and subjected to sensitivity testing; both colonies were methicillin-resistant S. 
aureus (MRSA). Sensitivity was limited to ABK, VCM, and TEIC only. One colony of 
Pseudomonas spp. was subjected to sensitivity test for the following antibiotics: ABPC, 
PIPC, CCL, CFPM, CEZ, CTM, CZOP, CAZ, CMZ, LMOX, IPM/CS, MEPM, AZT, 
GM, and AMK. This colony was resistant or showed intermediate resistance to ABPC, 
CCL, CFPM, CEZ, CTM, CMZ, LMOX, and AZT. This Pseudomonas spp. colony was 
sensitive to PIPC, CZOP, CAZ, IPM/CS, MEPM, GM, and AMK. Other bacteria 
identified were as follows: Neisseria spp. (n = 9), Corynebacterium spp. (n = 5), 
Enterococcus spp. (n = 3), and Haemophilus parainfluenzae (n = 2). All colonies were 
sensitive to most of the antibiotics tested. 
The results of the present study indicated there were many antibiotic-resistant 
bacteria in the oral cavity after HCT, especially during the period in which the severity 
of oral mucositis reached its peak. Oral mucositis could be a potential route of 
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antibiotic-resistant infections. In our previous study, bacterial substitution mainly of 
CoNS for streptococci occurred frequently on the oral buccal mucosa after HCT [1]. 
High levels of antibiotic resistance in CoNS may explain bacterial substitution of CoNS 
for streptococci. On the other hand, streptococci with antibiotic resistance and/or 
intermediate resistance have also been detected at relatively high frequencies. Note that 
two colonies of MRSA and one colony of Pseudomonas spp. resistant to many types of 
antibiotic were detected. These observations are a reminder of the risk of appearance of 
MRSA and/or multi-drug-resistant Pseudomonas aeruginosa (MDRP), and the oral 
cavity may be a site of MRSA and/or MDRP growth. Further studies regarding the 
association with bacteremia/sepsis by DNA fingerprinting will yield additional insight 
into the clinical relevance of the present findings. Examination of specific 
patient-related or therapy-related risk factors for developing resistance may contribute 
to determination of personalized importance of oral care before and after HCT. 
In conclusion, many antibiotic-resistant bacteria were detected in the oral 
cavity after HCT, especially during the period in which the severity of oral mucositis 
reaches its peak.  
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